METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Targeted radiation zaps advanced prostate cancer in new trial
Disease control OngoingThis study tested a targeted radiation drug called [177Lu]Lu-PSMA-617 in Chinese men with advanced prostate cancer that had spread and stopped responding to standard hormone treatments. The drug is designed to seek out and deliver radiation directly to prostate cancer cells. Rese…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Radioactive drug trial aims to control spreading prostate cancer
Disease control OngoingThis study is testing whether adding a standard hormone therapy to a newer radioactive drug works better than the radioactive drug alone for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. The radioactive drug (lutetiu…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New cancer drug enters human testing for Tough-to-Treat tumors
Disease control OngoingThis study is testing a new drug called NUV-1511 in adults with advanced solid tumors that have stopped responding to standard treatments. The first part checks the drug's safety and finds the right dose, while the second part looks at how well it shrinks tumors in specific cance…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Cancer drug safety watch: tracking Long-Term effects
Knowledge-focused ENROLLING_BY_INVITATIONThis study tracks the long-term safety of experimental cancer treatments in patients who previously participated in earlier Janssen trials. It follows 80 people with various cancers to monitor for serious side effects over time. The goal is to better understand the safety profile…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Knowledge-focused
Last updated Mar 11, 2026 14:54 UTC